2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC

D.Tripathy; C.Moisa; S.Glück

首页> 外文期刊>European Journal of Cancer Supplements >2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC

【24h】

2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC

机译：2129海报公开了一项卡培他滨（C）和多西他赛（D）作为新辅助治疗新确诊的HER2-neu阴性（HER2-–）乳腺癌（BC）加上曲妥珠单抗（T）HER2-neu阳性（HER2 +）的患者的开放性研究）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
D.Tripathy; C.Moisa; S.Glück;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 2060 POSTER An open-label study of neoadjuvant capecitabine (C) and docetaxel (D) with/without trastuzumab (T) to determine the role of p53 mutations in clinical and pathological responses in patients with recently diagnosed breast cancer (BC) [J] . P.Nancy, S.Truong, D.Tripathy, European Journal of Cancer Supplements . 2007,第4期

机译：2060海报一项新药卡培他滨（C）和多西他赛（D）联合/不联合曲妥珠单抗（T）的开放标签研究，旨在确定p53突变在最近诊断为乳腺癌（BC）的患者中的临床和病理反应中的作用
2. Neoadjuvant Pertuzuinab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (Pts) With HER2-Positive Breast Cancer (BC) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla2期

机译：新辅助性Pertuzuinab（P）和Trastuzumab（H）：HER2阳性乳腺癌（BC）患者（Pts）的4臂随机II期临床研究（NeoSphere）的生物标志物分析
3. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study [J] . Swain S. M., Ewer M. S., Viale G., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第3期

机译：Pertuzumab，Trastuzumab和标准的蒽环类和紫杉烷基化疗为Her2阳性局部乳腺癌（Berenice）患者的Neoadjuvant治疗：II期，开放标签，多中心，跨国心脏安全研究
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study [O] . Xiaosong Chen, Guolin Ye, Chenfang Zhang, 2016

机译：在三阴性和HER2阳性三阴性乳腺癌患者的新辅助治疗中不含蒽环类药物的多西他赛和环磷酰胺方案与多西他赛蒽环类和环磷酰胺方案持续恶化的结果相关：NATT研究的最新随访数据
7. Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain [O] . R Colomer, E Ciruelos, J De la Haba, 2016

机译：西班牙治疗腹膜康氏症患者腹膜癌患者腹膜癌，胸瘤和多西紫杉醇患者腹膜癌患者的新辅助化疗的成本实用性分析

2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC

著录项

相似文献

相关主题

期刊订阅